Longeveron Inc.

Ticker

LGVN

Website

Sector

Biotech

Tearsheet

Why Invest

In Phase 2 for Alzheimer’s disease, Aging Frailty, Hypoplastic Left Heart Syndrome. Granted Rare Pediatric Disease and Orphan Designation in Q4 2021 for Hypoplastic Left Heart Syndrome. Expected to initiate first ever allogeneic cell therapy trial for Frailty in Japan in 2022. Strong balance sheet: raised $50M in 2021. In house manufacturing and product development.

  

  1. Clinical stage biotech focusing on developing cellular therapies for aging-related conditions. Strong FCF expected in fiscal year ‘22